Anya Kim1,2,3,4
Esther García-García1,2,3,4
Marco Straccia2,3,4,5,6
Andrea Comella-Bolla2,3,4,5,6
Andrés Miguez2,3,4,5,6
Mercè Masana1,2,3,4
Jordi Alberch1,2,3,4,5*†
Josep M. Canals2,3,4,5,6*†
Manuel J. Rodríguez1,2,3,4*†- 1Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
- 2Institute of Neurosciences, University of Barcelona, Barcelona, Spain
- 3August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
- 4Network Center for Biomedical Research in Neurodegenerative Diseases, Barcelona, Spain
- 5Laboratory of Stem Cells and Regenerative Medicine, Department of Biomedical Sciences, Faculty of Medicine and Health Science, University of Barcelona, Barcelona, Spain
- 6Production and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, Barcelona, Spain
Huntington’s disease (HD) is an inherited neurodegenerative disorder in which the striatum is the most affected brain region. Although a chronic inflammatory microglial reaction that amplifies disease progression has been described in HD patients, some murine models develop symptoms without inflammatory microglial activation. Thus, dysfunction of non-inflammatory microglial activity could also contribute to the early HD pathological process. Here, we show the involvement of microglia and particularly fractalkine signaling in the striatal synaptic dysfunction of R6/1 mice. We found reduced fractalkine gene expression and protein concentration in R6/1 striata from 8 to 20 weeks of age. Consistently, we also observed a down-regulation of fractalkine levels in the putamen of HD patients and in HD patient hiPSC-derived neurons. Automated cell morphology analysis showed a non-inflammatory ramified microglia in the striatum of R6/1 mice. However, we found increased PSD-95-positive puncta inside microglia, indicative of synaptic pruning, before HD motor symptoms start to manifest. Indeed, microglia appeared to be essential for striatal synaptic function, as the inhibition of microglial activity with minocycline impaired the induction of corticostriatal long-term depression (LTD) in wild-type mice. Notably, fractalkine administration restored impaired corticostriatal LTD in R6/1 mice. Our results unveil a role for fractalkine-dependent neuron-microglia interactions in the early striatal synaptic dysfunction characteristic of HD.
Introduction
Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by motor, cognitive, and psychiatric disturbances. It is caused by a CAG repeat expansion in the huntingtin gene, leading to abnormal toxic aggregates of mutant huntingtin (mHtt). Neuropathology of HD is prominent in the striatum, the main primary input of basal ganglia (Morigaki and Goto, 2017) and the cerebral cortex, which extensively projects glutamatergic afferents to medium spiny neurons (MSNs) in the striatum. HD disrupts the mechanisms by which cortical and MSNs communicate before the onset of symptoms (Unschuld et al., 2012; Burgold et al., 2019), making corticostriatal pathway dysfunction a keystone in the pathophysiology of the disease (Miller et al., 2011; Wilkes et al., 2019). Some data from HD mouse models suggest that deficits in synaptic plasticity and neuronal processing are the cellular basis for this specific neurodegeneration. For example, loss of corticostriatal synapses (Deng et al., 2013), altered striatal long-term depression (LTD) (Cummings et al., 2007; Creus-Muncunill et al., 2019; Ghiglieri et al., 2019) and reduction of striatal excitatory postsynaptic currents (Cepeda et al., 2003) have been described in R6/1 mice, a transgenic model of HD. This progressive corticostriatal communication impairment markedly alters basal ganglia circuitry activity, ultimately leading to motor disturbances (Hong et al., 2012; Puigdellívol et al., 2015; Veldman and Yang, 2018).
Microglia, the resident immune cells of the CNS, are activated in the brain of HD patients years before clinical manifestations appear (Tai et al., 2007). Evidence suggests that early microglial activation is triggered by mHtt-mediated excitotoxicity and is one of the mechanisms mediating HD pathogenesis (Tai et al., 2007; Yang et al., 2017). However, the nature of such activation remains elusive and whether it presents beneficial or detrimental consequences in HD is still a matter of study. On the one hand, microglia in the striatum of patients and some HD models proliferate and present a classical inflammatory morphological phenotype (Sapp et al., 2001). These cells release neurotoxic pro-inflammatory cytokines, which results in microglial over-activation that finally aggravate HD progression (Crotti et al., 2014). On the other hand, activated microglia also produce anti-inflammatory cytokines and growth factors with trophic and neuroprotective functions (Yang et al., 2017). In HD, these contradictory functions of microglia can be found simultaneously. Thus, transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF), two characteristic biomarkers of alternative non-inflammatory microglial activation (Liu et al., 2013; Yang et al., 2017), have been reported to co-exist with pro-inflammatory cytokines in HD plasma and post-mortem brain tissue (Battaglia et al., 2011; Di Pardo et al., 2013; Chang et al., 2015). Additionally, HD microglial cells express high levels of mHtt (Ferrante et al., 1997) which induces cell-autonomous microglial pathogenic mechanisms (Crotti et al., 2014; Creus-Muncunill and Ehrlich, 2019; Siew et al., 2019). For example, mHtt impairs microglial motility in response to ATP in HD mice (Kwan et al., 2012) an impairment also observed in CX3CR1-KO mice (Pagani et al., 2015). This cellular dysfunction introduces a new element of complexity to the unclear role of microglia in HD.
In the healthy brain, microglia are continuously and actively scanning the brain environment, moving their processes and sensing neuronal activity without perturbing neuronal networks. Surveillant microglia phagocytose inactive synapses (Wake et al., 2009; Schafer et al., 2012) via expression of traditional immune complement molecules (Wake et al., 2013; Hong et al., 2016), and promote synapse and/or spine formation during development and after injury (Parkhurst et al., 2013; Miyamoto et al., 2016) and sensory experience (Tremblay et al., 2010) contributing to sculpt neuronal circuits.
In physiological conditions neurons specifically release fractalkine (FKN) to maintain the surveillant state of microglia (Ransohoff and Perry, 2009). FKN, also known as CX3CL1, is expressed as a membrane-bound glycoprotein that is proteolytically cleaved to release a soluble chemokine (Harrison et al., 1998). FKN modulates microglial motility, migration and activation by interaction with CX3CR1, its only specific receptor that in the brain parenchyma is restricted to microglia (Cardona et al., 2006; Chiu et al., 2013). The FKN-CX3CR1 axis not only contributes to maintaining the surveillant state of microglia but also has a role in modulating synaptic plasticity and neuronal survival (Rogers et al., 2011; Lauro et al., 2015; Luo et al., 2019). In the hippocampus, FKN-CX3CR1 interactions prevent glutamate-mediated excitotoxicity and apoptosis (Deiva et al., 2004) modulate glutamatergic synapses (Ragozzino et al., 2006; Paxinos and Franklin, 2012), and promote adenosine release by microglia (Lauro et al., 2010). Under pathological conditions FKN has conflicting effects on microglia, being neuroprotective and anti-inflammatory in some contexts, while pro-inflammatory and neurotoxic in others (Lauro et al., 2015). Therefore, abnormalities in the FKN-CX3CR1 axis may lead to dysfunction of non-inflammatory microglial activity and contribute to the pathological processes described in HD.
We hypothesized that changes in FKN-CX3CR1 interactions contribute to the striatal synaptic plasticity dysfunction characteristic of HD from early stages of the disease. To validate our hypothesis we used post-mortem striatal samples of HD patients, human induced pluripotent stem cells (hiPSC) derived striatal neurons, and R6/1 mice. This HD mouse model is extensively characterized, exhibiting an onset of motor symptoms from 14 to 15 weeks of age and a progressively severe disease phenotype (Mangiarini et al., 1996; Puigdellívol et al., 2015). Our results unveil a role for FKN-dependent neuron-microglia interactions in the early striatal synaptic dysfunction characteristic of HD.
Materials and Methods
HD Mouse Model
Male and female R6/1 transgenic mice expressing the human exon-1 of mHtt containing 115 CAG repeats and their corresponding wild-type (WT) littermates were obtained from Jackson Laboratory (Bar Harbor, ME, United States) and maintained in a B6CBA background. Polymerase chain reaction (PCR) from tail biopsy samples was used to determine genotypes. Animals were housed together in groups of mixed genotypes and kept under a 12:12 h light/dark cycle in a room at 19–22°C and 40–60% humidity, with free access to food and water. Mouse identification and data analysis were recorded by microchip mouse number. All animal procedures were approved by the animal experimentation Ethics Committee of the University of Barcelona in accordance with the regulations established by the Catalan government, the Spanish regulation (RD 53/2013) and European guidelines (2010/63/UE for the care and use of laboratory animals.
Human Post-mortem Nervous Tissue
Human post-mortem tissue samples of putamen were used to assess FKN expression and concentration. These samples were obtained from the Neurological Tissue Bank of the Biobanc-Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS, Barcelona, Spain1), following the guidelines and approval of the Ethics Committee of the University of Barcelona and the European ethical guidelines. Samples were collected at autopsy from individuals who had suffered a clinical history of HD (n = 8, age: 62.5 ± 7.2 years; postmortem intervals of 4–18 h), and from non-HD controls (n = 12, age: 54.5 ± 6.5 years; postmortem intervals of 4–17 h). Samples were fresh-frozen and stored at −80°C for quantitative real-time PCR (qRT-PCR) and western blot analysis.
Human iPSC Culture, Differentiation and Immunostaining
Two human iPSC lines were employed in this study. Firstly, the CS83iCTR-33nXX (CTR33) line was used, which was derived from an unaffected sibling of a HD patient with genotyped CAG repeat length of 33 in the HTT gene. This line was reprogrammed using a non-integrating strategy and was developed as a “control” line for a related study on HD hiPSC characterization (Telezhkin et al., 2018). Secondly, the CS21iHD60n5 (HD60) line was used (Hd iPSC Consortium, 2017) which was derived from an HD juvenile patient and re-programmed using integrating vectors.
HiPSC lines were cultured and differentiated as previously described (Comella-Bolla et al., 2020). In brief, cells were kept in the pluripotent state using mTeSRTM1 (Stem Cell Technologies, Grenoble, France) on BD Matrigel-coated plates (BD Biosciences, Oxford, Oxon, United Kingdom), and differentiated to neural progenitors using an in-house differentiation protocol as described elsewhere (Comella-Bolla et al., 2020).
Immunocytochemistry
HiPSC-derived cultures at DIV 37 were fixed at room temperature with 4% (w/v) paraformaldehyde (Fisher Scientific UK Limited, Leicestershire, United Kingdom), washed in PBS and stored at 4°C in 0.03% Sodium-Azide (Sigma-Aldrich, Madrid, Spain) PBS until use. For immunolabeling, samples were blocked and permeabilized for 45 min with PTB solution [PBS with 0.3% Triton X-100 (Sigma-Aldrich), 0.03% Sodium-Azide, 1% BSA (Sigma-Aldrich) and/or 5% Normal Goat serum (Vector Laboratories Ltd., United Kingdom) and 5% Donkey Serum (Jackson Immuno Research Laboratories Inc.; PA, United States)], before being incubated overnight at 4°C with primary antibodies (Table 1). After overnight incubation, samples were washed with PBS. Then cells were incubated for 90 min at room temperature in darkness in smooth motion with appropriated fluorophore-conjugated secondary antibodies (Table 1). After washing in PBS, cells were counterstained with DAPI (4′,6-diamidino-2-phenylindole) for nuclear staining (Thermo Fisher Scientific, Waltham, MA, United States). Coverslips were mounted in Fluoromount-G media (Southern Biotech, AL, United States) and imaged using a Leica SP5 TCS Two-photon laser scanning confocal microscope (Leica Microsystems Heidelberg GmbH, Mannheim, Germany). FKN staining was quantified using the open-access CellProfiler software (BROAD institute, MA, United States). Three independent experiments were run in parallel for each cell line, CTR33 and HD60, from which we analyzed two replicas. Three to five pictures of fields of view were taken with the epifluorescence Leica AF600 microscope (Leica Microsystems, Wetzlar, Germany). For each picture we analyzed (1) the total area covered by MAP2B staining to assess the neuronal density and (2) the mean intensity of FKN staining.
Table 1. List of antibodies used in the study.
Quantitative Real-Time PCR
Aqueous phase containing total RNA was isolated from human and mouse brain regions or cells using TRI Reagent (Sigma-Aldrich) following the manufacturer’s protocol. Then total RNA was purified with Direct-zol RNA MiniPrep Plus (Zymo Research, Irvine, CA, United States). A range of 0.25 to 1 μg of RNA for each condition was reverse transcribed using a PrimeScript RT reagent kit (Takara, Japan). The RT reaction was performed at 42°C for 60 min followed by an additional 5 min at 70°C. cDNA was diluted to 5 ng/μL and 2 μL was used to perform qRT-PCR. PrimeTime qPCR assays (Table 2) were used as recommended by provider (IDT technologies, United States). qRT-PCR was carried out with Premix Ex Taq (RR390A, Takara, Japan) in 6 μL final volume using a CFX384-C1000 thermal cycler (Bio-Rad Laboratories, Madrid, Spain). The two-step amplification program was: 40 cycles of 2 min at 95°C for denaturation and polymerase activation, 5 s at 95°C for denaturation, and a final extension for 20 s at 60°C. For each target gene, the expression level was determined using a standard curve (efficiency between 93 and 100%) and normalized to housekeeper gene mRNA levels. Reactions were performed in triplicate to reduce variability. The ΔΔCt method was used to analyze the data.
Table 2. PrimeTime qPCR assays used in the study.
Western Blot Analysis
Total protein extracts were obtained after organic separation and homogenization of samples in TRI Reagent (Sigma-Aldrich) following the manufacturer’s instructions. Protein concentration was determined by the Bradford assay (Bio-Rad Laboratories). Western blot analyses were performed as described previously (Comella-Bolla et al., 2019). In brief, 20 μg of total protein extracts were subjected to 10% SDS-PAGE, then proteins were transferred to Nitrocellulose membrane (Amersham Pharmacia Biotech, San Francisco, CA, United States) and probed by incubation with either anti-β-actin or anti-FKN primary antibodies, washed and incubated with appropriate secondary antibodies (Table 1). Chemiluminescent detection was performed by incubating with Luminata Classico Western HRP Substrate (Millipore, Burlington, MA, United States) and exposure to Fuji Medical X-Ray Film Super RX-N (Fujifilm, Japan). Western blot quantification was performed on digital acquired films by using ImageJ Gel Analysis. Data were expressed as the ratio between the band intensity of the protein of interest and that of β-actin. The relative ratio between FKN immunoreactive bands was also calculated.
Immunohistochemistry and Image Analysis
Wild-type and R6/1 mice were sacrificed via cervical dislocation. Brains were isolated and post-fixed overnight with 4% paraformaldehyde, cryoprotected with 30% (w/v) sucrose in PBS, frozen in dry ice and stored at −80°C until sectioning. Serial 40 μm sections were obtained at level 2.4 mm anterior to Bregma on the cryostat, and stored in 0.02% Sodium-Azide (w/v) in PBS at 4°C until use. To label post-synaptic glutamatergic spines and microglial cells, double immunohistochemistry was performed with anti-PSD-95 and anti-Iba1 antibodies, respectively, as previously described (Espinosa-Parrilla et al., 2015). Briefly, sections were first washed in PBS containing 0.3% (v/v) Triton X-100. They were then incubated with 50 mM NH4Cl in PBS for 15 min. After a new washing with 0.3% Triton-X100 PBS, sections were incubated with a blocking solution of PBS containing 0.3% Triton-X100 and 10% Normal Goat Serum for 2 h. Sections were then co-incubated overnight at 4°C with both anti-Iba1 and anti-PSD-95 antibodies (Table 1). After washing in the blocking solution, sections were then incubated for 2 h with combinations of appropriate secondary antibodies (Table 1). All antibodies were diluted in the previously described blocking solution. Incubations with either mouse or rabbit IgG as primary antibodies were used for negative controls. All washes and incubations were done at room temperature, except for the primary antibody incubation, which was done at 4°C. After antibody incubations, slices were washed, incubated in DAPI, mounted with Fluoromount-G and kept in the dark.
Stereological counting of microglial cells was preformed on Iba-1 single immunostained sections. Striatal regions were outlined at 2.5× magnification on arbitrary uniform random (AUR) coronal sections. Individual cells were viewed at 40× and then counted. We applied the FIJI Auto Local Threshold plugin followed by the Analyze Particles Plugin for ImageJ to identify and analyze cells. For the microglial morphological analysis, series of confocal images from Iba-1-immunostained sections were acquired at 63× (oil immersion, 1.5 μm step size and a zoom of 1×) using a Leica SP5 Two-photon confocal microscope. Microglial morphology was semi-automatically processed in 3D using 3DMorph, a MATLAB-based program developed by York et al. (2018). For image acquisition and processing the voxel sizes were 0.241 μm in the XY plane with a 1.5 μm step size. Only the 488 nm channel (labeling the Iba-1 stained cells) was used for picture acquisition, and all cell processes (small and large) were used in our analysis. The microglial cell parameters analyzed were: cell volume, territorial volume, cell complexity (estimated as the quotient cell territory/cell volume), the number and longitude of cell processes and the number of endpoints. For every image acquired, 7–10 full cells were isolated and analyzed. To determine the relative amount of PSD-95-immunopositive puncta inside of Iba1-positive cells, confocal images were acquired at 63×, a 130 nm step size and a zoom of 3.5×. Then, images were processed with Imaris (Oxford Instruments, United Kingdom) to create a 3D reconstruction of microglia and count the post-synaptic puncta inside them (Supplementary Video). The images were prepared and rendered, and the relative amount of PSD-95 positive puncta engulfed by microglia was calculated using the engulfment assay described by Schafer et al. (2014).
Electrophysiological Field Recordings
Wild-type and R6/1 mice were sacrified via cervical dislocation. Brains were quickly removed and immersed on oxygenated (95% O2, 5% CO2) ice-cold aCSF containing (in mM) 124 NaCl, 24 NaHCO3, 13 glucose, 5 HEPES, 2.5 KCl, 2.5 CaCl2, 1.2 NaH2PO4 and 1.3 MgSO4. Mouse brain sagittal sections were obtained on a vibratome (Microm HM 650 V, Thermo Fisher Scientific, Waltham, MA, United States) at 350 μm thickness in oxygenated ice-cold aCSF. Slices were then transferred to an oxygenated 32°C recovery solution of the following composition (in mM): 92 NMDG, 30 NaHCO3, 25 glucose, 20 HEPES, 10 MgSO4, 5 sodium ascorbate, 2.5 KCl, 1.2 NaH2PO4, 3 sodium pyruvate, 2 thiourea, and 0.5 CaCl2; at 32°C for 15 min (Choi et al., 2019). Then, slices were transferred to oxygenated aCSF at room temperature and left for at least 1 h before recording.
For recording, slices were placed in a multi electrode array (MEA) recording dish and fully submerged in oxygenated aCSF at 34°C. Electrophysiological data were recorded with a MEA set-up from Multi Channel Systems MCS GmbH (Reutlingen, Germany) composed of a 60 channels USB-MEA60-inv system with a blanking unit from Multi Channel Systems and a STG4004 current and voltage generator. Experiments were carried out with 60MEA200/30iR-ITO MEA dishes consisting of 60 planar electrodes (30 μm diameter) arranged in an 8 × 8 array (200 μm distance between neighboring electrodes). Software for stimulation, recording and signal processing were MC Stimulus and MC Rack from Multi Channel Systems. Using a digital camera during recording assessed the position of the brain slices on the electrode field and the location of the laser for stimulation.
Striatal field post-synaptic currents (fPSC) were recorded in the dorsal striatum in response to stimulation of cortical afferents. One MEA electrode located at 2.4–2.1 mm lateral to bregma, 0.8–0.6 mm anterior to bregma, and 2.2–2.3 mm depth from brain surface was set as stimulation one (Figure 5A), and fPSC were evoked by single monopolar biphasic pulses (negative/positive, 100 μs per phase). For input/output curves, corticostriatal fibers were stimulated with trains of three identical pulses at increasing currents (250–3000 μV). The pulse amplitude of subsequent stimuli was set to evoke 40% of the saturating fPSC. LTD was induced by theta-burst stimulation (TBS) consisting of 10 trains spaced 15 s apart. Each train consisted of 10 bursts at 10.5 Hz (theta), and each burst consisted of four stimuli at 50 Hz (Figure 5B). Thus, the whole TBS stimulation period lasted 2.5 min (Hawes et al., 2013). To determine the effects of microglial activity in striatal fPSC evoked by stimulation of cortical afferents, slices were incubated with either 100 μM minocycline (Mino) (Sigma-Aldrich) (Song et al., 2015; Acharjee et al., 2018) or 2 nM FKN (PeproTech, London, United Kingdom) (Bertollini et al., 2006; Liu et al., 2015; Pandur et al., 2019) from 30 min prior to and during electrophysiological recordings.
Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM). Homogeneity of variance was checked using Levene’s test. Analyses were performed by the unpaired Student’s t-test, analysis of variance (ANOVA), or repeated measures two-way ANOVA. Variance main components were analyzed with either genotype and age, or genotype and treatment as factors by the Bonferroni post hoc test. Values of p < 0.05 were considered significant. Analyses were performed with the SPSS Statistics v25 (IBM Corp., United States) statistical package.
Results
HD Induces an Early Decrease in Striatal Fractalkine Levels
Since microglia have been proposed to contribute to the HD pathological process, and the FKN-CX3CR1 axis has a central role in controlling microglial activity, we first analyzed the effects of mHtt on CX3CR1 and FKN expression in the striatum of R6/1 mice at different ages (1, 8, 12, 20, and 30 weeks of age). After mRNA quantification by qRT-PCR, we found no CX3CR1 expression changes in the striatum of R6/1 mice when compared with WT animals at any of the ages studied (Figure 1A). However, we observed a significant 66% reduction in FKN expression in the striatum of R6/1 mice at 8 weeks, before disease symptoms arise, compared with WT (t = 18.74; p < 0.0001). We found a similar FKN mRNA decrease in R6/1 mice at 12, 20, and 30 weeks (t = 3.26, p = 0.010; t = 15.66, p < 0.0001; t = 13.45, p = 0.0009, respectively) (Figure 1B). When we compared FKN protein levels between WT and R6/1 mice, we observed a significant decrease in the striatal FKN concentration of R6/1 mice at 6, 8, 12, and 20 weeks (t = 2.599; p = 0.038; t = 5.108, p = 0.0002; t = 3.195, p = 0.016; and t = 2.700, p = 0.036, respectively) but not at 30 weeks of age (Figure 1C). Similarly we observed a significant 44% reduction in FKN expression in the cortex of R6/1 mice at 20 weeks (t = 5.299, p = 0.0018), whereas the CX3CR1 gene expression remained unvaried (Supplementary Figure 1).
Figure 1. Fractalkine levels are decreased in the striatum of R6/1 mice. Histograms show the mHtt-induced fold change of CX3CR1 (A) and FKN (B) expression quantified by qRT-PCR in the striatum of R6/1 male mice relative to WT littermates (1-week WT n = 3, 8-week WT n = 5, 12-week WT n = 8, 20-week WT n = 6, 30-week WT n = 4; 1-week R6/1 n = 7, 8-week R6/1 n = 5, 12-week R6/1 n = 10, 20-week R6/1 n = 6, 30-week R6/1 n = 4) (C) Quantification (left) and representative immunoblots of striatal lysates (right) of FKN levels at different ages of R6/1 mice and their corresponding WT littermates. β-actin was used as loading control. Data are expressed as a percentage of WT mice. (n = 3 mice/group, except the 8-week R6/1 group with n = 5). Two-tailed unpaired t-test; *p < 0.05; **p < 0.01.
We next assessed whether these FKN changes in R6/1 mice were also present in the putamen of HD patients and in striatal neurons derived from cultured HD hiPSCs. We found a significant reduction in FKN gene expression in the putamen of HD patients with respect to controls (t = 2.792, p = 0.0068) by qRT-PCR (Figure 2A). This reduction was also found when we measured the striatal protein concentration of FKN by western blot (Figure 2B). Cells derived in vitro from hiPSCs showed differences in FKN gene expression depending on the stage of differentiation (F(1,8) = 165, p < 0.0001). We found low FKN expression in cells at neuroblast stage (DIV 16), whereas mature striatal neurons (DIV 37) presented high FKN gene expression (Figure 2C). This increase in FKN gene expression was smaller in mature neurons derived from HD hiPSCs (F(1,8) = 122.3, p < 0.0001) relative to controls (Figure 2C). Immunocytochemical staining performed in cultured hiPSCs at DIV 37 showed intense FKN staining in neurites of mature neurons derived from control hiPSCs (Figure 2D). A reduction in FKN immunostaining was observed in neurites of neurons derived from the HD patient, when compared with controls (t = 2.188, p = 0.047; Figure 2D). These results indicate that asymmetric changes in the FKN-CX3CR1 axis occur during striatal HD pathogenesis, specifically modifying FKN levels.
Figure 2. Fractalkine expression is decreased in human HD striatum and hiPSC-derived striatal neurons. (A) HD-induced changes of FKN expression quantified by qRT-PCR in human putamen relative to controls (HD cases n = 6; controls n = 11) (B) Quantification and representative immunoblots of FKN levels in human putamen. β-actin was used as loading control (*p = 0.035, Student t-test; n = 6 cases/group). (C) HD-induced changes of FKN expression quantified by qRT-PCR in HD60 iPSC-derived neuroblasts (DIV 16) and neurons (DIV 37) relative to Ctrl33 controls. ΔCT values are relative to housekeeping gene values (n = 3 cultures/group). *p < 0.05, two-tailed unpaired t-test; **p < 0.01, Bonferroni post-hoc test. (D) Confocal photomicrographs of FKN immunostaining (green) in cultured neurons (MAP2-positive; red) derived from Ctrl33 and HD60 iPSCs. Cellular nuclei are stained with Dapi (blue). Analysis of green channel picture (488 nm, black and white image, FKN) and quantification of FKN-staining intensity relative to the MAP2-stained area denotes widespread FKN staining in Ctrl33 cells, which is decreased in neurites of HD60 cells. *p < 0.05, two-tailed unpaired t-test (n = 3 cultures/condition). Scale bar: 14 μm.
R6/1 Microglia Exhibit a Non-inflammatory Morphology
The asymmetric changes found in FKN signaling pointed to modifications in microglial activity, since microglia are the only cells in the brain parenchyma that express the FKN receptor CX3CR1 (Nishiyori et al., 1998). Therefore, FKN decrease in the striatum of R6/1 mice could potentially affect microglial behavior in this HD model. We first analyzed changes in microglial proliferation and morphology associated with classic inflammatory activation in pre-symptomatic mice (12 weeks of age) and symptomatic mice presenting motor symptoms (20 weeks of age). We found no genotype-induced changes in the number of Iba-1 immunostained microglia (Figures 3A,B). To visualize any broad morphological changes in microglia potentially indicative of a classical inflammatory response, we performed a detailed analysis with 3DMorph (Figure 3D), a sensitive program that allows analyzing many different morphological parameters (York et al., 2018). In all cases, we observed a surveillant ramified microglial shape (Figure 3C). We found no effects of phenotype or age in either the microglial cell volume, the territory occupied by the cells, the microglial cell complexity, the number and length of cell processes, or the number of endpoints (Figure 3D).
Figure 3. Lack of inflammatory morphology of microglia in 12-week-old R6/1 mice. (A) Illustrative Iba-1 immunostaining images of the striatum from WT and pre-symptomatic R6/1 mice (12 weeks of age). Scale bar: 40 μm. (B) Quantitative analysis of the number of Iba-1 positive cells per section. Data are expressed as a percentage of WT values (WT n = 3 female + 5 male mice, R6/1 n = 3 female + 3 male mice). (C) Illustrative images of 3DMorph analysis of individual microglial cells isolated from confocal microphotographs. From each full cell volume, 3D skeletons were generated and then processed to obtain an image of either major branches or branch end points. In skeleton figures, colors indicate order of connectivity (red = primary, yellow = secondary, green = tertiary, and blue = connected to end point). (D) Quantitative analysis of the microglial cell volume, territory occupied by each cell, microglial cell complexity (cell territory/cell volume), number and longitude of cell processes, and number of endpoints. (WT n = 3 female + 4 male, R6/1 n = 3 female + 3 male mice).
Increased Microglial Engulfment of PSD-95-Positive Puncta in R6/1 Mice
In spite of the absence of microglial morphological changes, FKN decrease in the striatum of R6/1 mice could potentially be affecting the non-inflammatory activity of microglia. Since FKN has been proposed to play an important role in regulating microglia-mediated synaptic pruning (Gunner et al., 2019) we estimated the density of PSD-95 immunopositive puncta in the dorsal striatum of pre-symptomatic mice (12 weeks of age) and symptomatic (20 week of age) R6/1 mice (Figure 4A). Density of PSD-95 immunopositive puncta was decreased by 71% in the dorsal striatum of R6/1 mice at 20 weeks of age (t = 4.205; p = 0.003) relative to WT, whereas the 31% reduction found at 12 weeks of age did not reach significance (t = 1.788; p = 0.107) (Figure 4A). To estimate the microglial contribution to this decrease we quantified the number of PSD-95 puncta engulfed by microglia at 12 weeks of age using a synaptic engulfment assay (Supplementary Video and Figures 4B,C). We found a 27% increase in the number of PSD-95 positive puncta inside Iba1-stained microglia in the dorsal striatum of R6/1 mice relative to WT (t = 3.051; p = 0.015). However, we found no expression changes of microglial genes involved in phagocytosis and trophic microglial activities in the striatum of 20-week-old R6/1 mice compared with WT (Supplementary Figure 2). These results point toward an abnormal increase in microglial synaptic engulfment in pre-symptomatic HD animals that could contribute to the progressive loss of synapses and striatal dysfunction.
Figure 4. Microglia increases PSD-95-positive puncta engulfment in 12-week-old R6/1 mice. (A) Illustrative confocal images of PSD-95 immunostaining and quantitative analysis of the number of PSD-95-positive puncta per section in the striatum of WT and R6/1 mice of 12 and 20 weeks of age. Graph data are expressed as a percentage of WT values. (B) Illustrative confocal images of Iba-1 (green) and PSD-95 (red) double immunostaining in the striatum of WT and R6/1 mice at 12 weeks of age. (C) Three-dimensional microglia reconstruction and surface rendering by means of Imaris software showing larger relative numbers of PSD-95 positive puncta inside Iba-1 positive cells in R6/1 mice. Data are expressed as a percentage of engulfed puncta in WT striatum. *p = 0.0158; **p = 0.003, two-tailed unpaired t-test (n = 2 female + 3 male mice/group). Scale bar: 15 μm in a and b; 7 μm in c.
Microglial Activity Is Essential for Corticostriatal Synaptic Long-Term Depression
We next explored whether microglial activity has a role in corticostriatal synaptic plasticity such as LTD induction, which is known to be altered in HD mice (Creus-Muncunill et al., 2019). We recorded fPSC in the dorsal striatum after electrical stimulation of cortical afferents in sagittal slices (Figure 5A). In all recordings we selected a stimulus pulse to evoke the 40% of the saturating fPSC in an input/output curve. In these conditions, the amplitude of evoked fPSC in the striatum of R6/1 mice decreased 54% compared with WT (F(1,18) = 4.52, p = 0.0048), whereas the presence of either 100 μM Mino or 2 nM FKN in the bath did not modify basal fPSC amplitude (Figures 5C,D). To evaluate synaptic dysfunction, we induced LTD using a TBS protocol (Figure 5B) and compared the amplitude of evoked striatal fPSC. We analyzed the effect of microglial activity depletion over LTD by adding 100 μM Mino in the bath (Figures 5C–E). After two-way ANOVA analysis, we found fPSC amplitude differences among the four mouse groups (WT-Ctrl, WT-Mino, R6/1-Ctrl, and R6/1-Mino) 30 min after LTD induction (F(3,20) = 13.88, p < 0.0001). Factor analysis showed genotype (F(1,20) = 27.62, p < 0.0001) and drug (F(1,20) = 5.838, p = 0.028) effects, and genotype/drug interactions (F(1,20) = 13.174, p = 0.002). According to the Bonferroni post-hoc test, TBS induced a decrease in the fPSC amplitude only in WT-Ctrl mice (Figure 5E), while LTD was not induced in WT-Mino nor R6/1-Ctrl and R6/1-Mino groups. These results suggest that microglial activity is essential for corticostriatal synaptic plasticity.
Figure 5. Microglia are essential for long-term depression and fractalkine restores corticostriatal synaptic plasticity in 12-week-old R6/1 mice. (A) Drawing of a mouse brain sagittal section showing the location of stimulating and recording electrodes for corticostriatal fPSC recordings (adapted from Paxinos Mouse Brain Atlas). (B) Schematic of the TBS paradigm for LTD induction. A single train of stimuli is illustrated in brackets and annotated to show the stimuli number and frequency, as well as the time scale. (C) Representative fPSC traces prior to TBS (pre-TBS, black) and after TBS (post-TBS, blue) in the six conditions of electrophysiological recordings. (D) Histograms show the quantification of fPSC amplitude in the striatum of WT and R6/1 mice relative to WT (n = 10 male mice/group), and in the presence of either 100 μM minocycline (Mino; n = 5 male mice/group) in the bath or 2 nM fractalkine (FKN; n = 5 male mice/group) in the bath, relative to absence in the bath (Ctrl). fPSC amplitude was calculated as the mean of 30 different fPSC evoked every 30 s during 15 min prior to TBS. One-factor ANOVA test; *p < 0.05 different from WT (E,F) Graphs show the time course and quantification of fPSC evoked at corticostriatal synapses and the LTD induced after a TBS (arrow) in presence or absence of either (E) 100 μM Mino in the bath (n = 5 male mice/group) or (F) 2 nM FKN in the bath (n = 5 male mice/group). fPSC amplitudes are represented as a percentage of baseline. Histograms show the mean amplitude of fPSC evoked at 29–30 min after TBS. Bonferroni’s Multiple Comparison post hoc test; *p < 0.05, **p < 0.01, different from WT-Ctrl; #p < 0.05 different from R6/1-Ctrl.
Fractalkine Restores Corticostriatal Long-Term Depression in R6/1 Mice
We then evaluated the putative role of FKN in corticostriatal LTD dysfunction in R6/1 mice by adding 2 nM FKN in the bath (Figures 5C,D,F). In these conditions, we found fPSC amplitude differences among the four mouse groups (WT-Ctrl, WT-FKN, R6/1-Ctrl, and R6/1-FKN) 30 min after LTD induction (two-way ANOVA, F(3,20) = 9.474, p = 0.001). Factor analysis showed effects of genotype (F(1,20) = 19.330, p = 0.0004) and treatment (F(1,20) = 5.581, p = 0.031), but not genotype/treatment interaction (F(1,20) = 3.512, p = 0.0792). According to the Bonferroni post hoc test, TBS decreased the fPSC amplitude in WT-Ctrl, WT-FKN, and in R6/1-FKN mice, although the magnitude of the induced LTD in these animals was smaller than the one observed in WT mice (Figure 5F). These results indicate that a lack of FKN is involved in striatal synaptic plasticity dysfunction in pre-symptomatic R6/1 mice.
Discussion
Microglia have long been regarded as a mere driver of chronic inflammation in neurodegenerative diseases. With the present work, we make a meaningful contribution to the growing appreciation that their role is much more nuanced. In our HD mouse model, we found no gross, inflammatory microglial morphological changes. Instead, 3D reconstruction allowed us to visualize an increase in their engulfment of post-synaptic material, potentially driven by changes in neuronal FKN. Our data also highlight the role for microglia in altering the electrophysiological characteristics of corticostriatal synapses, specifically LTD, with FKN being central in modulating this microglial homeostatic function.
FKN-CX3CR1 signaling depletion is often correlated with increased neuroinflammation (Bachstetter et al., 2011). In response to pathogenic stimuli microglia acquire a pro-inflammatory profile and decrease CX3CR1 expression or activity (Ransohoff and Perry, 2009). Similarly, CX3CR1 polymorphisms that decrease receptor activity or affinity for FKN are linked to enhanced disease progression in amyotrophic lateral sclerosis (Lopez-Lopez et al., 2014; Calvo et al., 2018), Alzheimer’s disease (Finneran and Nash, 2019) and neuroinflammatory pathologies (Arli et al., 2013; Cardona et al., 2018). More interestingly, knocking out CX3CR1 in Alzheimer’s disease mice showed reduced Aβ deposition and increased microglial phagocytic activity (Liu et al., 2010). Also, a recent article showed that lowering CX3CR1 levels or partially inhibiting its activity in the brain might be a therapeutic strategy to increase neuronal Aβ clearance, reduce Aβ levels and delay progression of Alzheimer’s disease (Hickman et al., 2019). These studies suggest that a decrease in microglia-neuron communication, caused by a reduction of FKN-CX3CR1 signaling, is sufficient for losing the anti-inflammatory and homeostatic function of microglia, likely also affecting physiological processes (Chamera et al., 2019).
Interestingly, we found no significant changes in CX3CR1 expression in R6/1 mice over time, but instead a significant drop in FKN expression. These results are consistent with two previous gene expression analyses showing an mHtt-induced decrease in FKN expression in STHdhQ111/Q111 cells (Lee et al., 2007) and the striatum of 12-week-old R6/2 mice (Vashishtha et al., 2013). Additionally, in our study the FKN decrease preceded the onset of symptoms, with no inflammatory microglial morphological changes. Furthermore we observed no expression changes in any of the microglial genes analyzed in the striatum of 20-week-old, symptomatic R6/1 mice. Based on these data, pathological changes in the FKN-CX3CR1 axis could instead be driven by mHtt-induced changes in neuronal FKN production, rather than by microglial deregulation. This result is confirmed by other studies showing a lack of inflammatory markers in the striatum of non-symptomatic R6/1 mice (Pérez-Severiano et al., 2002; Renoir et al., 2015). In this line, a systems biology analysis of different HD mouse models reported wide mHtt-induced gene expression deregulation in the striatum in a CAG-length dependent manner (Veldman and Yang, 2018). In this study the main group of deregulated proteins was involved in synaptic processes and included decreased FKN expression. Furthermore, network analysis of human post-mortem expression microarrays revealed FKN as an important novel factor in HD pathogenesis and survival (Chandrasekaran and Bonchev, 2016). Further detailed studies might characterize the molecular pathways involved in the mHtt-induced FKN down-regulation.
Fractalkine has been proposed to act in the adult brain as a neuronal signal maintaining microglia in a surveillant state (Ransohoff and Perry, 2009). Conversely, other studies reported decreased release of inflammatory factors and attenuated microglial activation in the striatum of both CX3CR1-knockout (KO) and knockdown mice after experimental ischemia (Tang et al., 2014; Liu et al., 2015) and in CX3CR1-KO mixed cultures (Mattison et al., 2013). Furthermore, decreased FKN gene expression was also observed in aged BACHD mice lacking metabotropic glutamate receptor 5, which was proposed to account for decreasing microglial activation in these mice (Carvalho et al., 2019). These studies suggest instead a role for FKN in the pro-inflammatory signaling of activated microglia different to that of surveillant microglia.
Our results suggest that decreased FKN may be modifying the role that microglia play in synaptic plasticity. Moreover, it has been proposed that FKN could play an important role in regulating synapse engulfment by microglia (Gunner et al., 2019). Previous studies demonstrated a reduction of MSN spine density in the striatum of 3-month-old YAC128 mice (Marco et al., 2013) and in hippocampal apical dendrites from R6/1 mice (Miguez et al., 2015). Also in R6/1 mice, decreased PSD-95 levels, which may affect the strength and number of synaptic contacts, have been proposed to be in the basis of the functional alterations observed in HD (Nithianantharajah et al., 2008). Accordingly, PSD-95 levels are decreased in the striatum of symptomatic knock-in HdhQ7/Q111 mice, and this correlates with a drop in the number of PSD-95 immunopositive puncta and altered corticostriatal long-term potentiation (Puigdellívol et al., 2015). We here describe for the first time changes in engulfment of PSD-95 immunopositive puncta by striatal microglia at pre-symptomatic stages of HD, which could contribute to the progressive loss of synapses and striatal dysfunction. Increased microglia-mediated engulfment of synaptic material has been described in mouse models of Alzheimer’s disease (Hong et al., 2016), schizophrenia (Sekar et al., 2016), and Rett syndrome (Derecki et al., 2012) via expression of traditional immune complement molecules (Hong et al., 2016; Sekar et al., 2016). These findings suggest that excessive microglia-mediated synaptic engulfment leads to synaptic dysfunction and could constitute a common pathological mechanism for many neurological and psychiatric pathologies. Whether environmental enrichment increases PSD-95 levels and improves cognition through improving microglia-neuron signaling in HD should be further explored.
Early corticostriatal LTD dysfunction in HD has been widely observed in R6/1 mice and other HD models (Cummings et al., 2007; Creus-Muncunill et al., 2019; Ghiglieri et al., 2019) and is considered one of the abnormal synaptic mechanisms of the disease (Unschuld et al., 2012; Burgold et al., 2019). We here found that depletion of microglial activity with Mino induced a decrease in corticostriatal LTD in WT mice, suggesting that microglial activity is essential for striatal synaptic function. Similar results in mouse hippocampus also suggest a role for microglia in modulating synaptic plasticity. For example, Mino has been reported to prevent the impairment of hippocampal long-term potentiation in a mouse model of Alzheimer’s disease (Wang et al., 2004) and in experimental sepsis-associated encephalopathy (Hoshino et al., 2017). Interestingly, depletion of microglial activity has also been associated with reduced synaptic pruning in the basolateral amygdala of an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis (Acharjee et al., 2018). In this line, FKN-induced partial restoration of LTD in R6/1 is also a new finding, further strengthening a role for impaired neuron-microglia communication in the early striatal synaptic dysfunction characteristic of HD.
The specific mechanism linking microglial homeostatic activity with this LTD impairment is still to be determined, but a role of FKN in synaptic plasticity has been previously suggested, with controversial results. CX3CR1-deficient mice show impaired synapse development during the early post-natal period (Hoshiko et al., 2012), which is associated with weak synaptic transmission and impaired functional connectivity (Zhan et al., 2014). In this line, juvenile CX3CR1-KO mice showed increased hippocampal LTD when compared with WT, but no modifications in the adult hippocampus (Paolicelli et al., 2011). Accordingly, clinical and experimental studies suggest that mHtt-induced aberrant development is at the root of some HD functional alterations (Molero et al., 2016; Hd iPSC Consortium, 2017; Van der Plas et al., 2019), in particular cortical neurons are hyperexcitable and display dysmorphic processes (Cepeda et al., 2019). Alterations in the FKN-CX3CR1 axis could contribute to this pathological development, as this signaling system is critical for functional maturation of synapses (Hoshiko et al., 2012). Conversely, disruption of FKN-CX3CR1 signaling in adult WT mice results in hippocampal long-term potentiation impairment leading to a loss of synaptic plasticity and cognitive dysfunction (Rogers et al., 2011). This loss of hippocampal synaptic plasticity was accompanied by an increase of IL-1β expression and p38 phosphorylation (Rogers et al., 2011). Interestingly, a significant increase in phosphorylated p38 levels has also been described in the striatum of 20-week-old R6/1 mice (Saavedra et al., 2011). Thus, further studies might provide evidence on a putative mechanistic link between FKN, phosphorylated p38, IL-1β release and the loss of striatal synaptic plasticity from post-natal development and adulthood to the onset of symptoms in HD.
Another mechanism of canonical neuron-microglia communication involves the CD200-CD200R1 axis. As described for FKN, CD200 is expressed by neurons and interacts with its specific receptor CD200R1, mostly expressed by microglia in the brain (Shrivastava et al., 2012). Recent work reported increased neuronal CD200 gene expression and protein levels in the brain parenchyma, along with HD pathogenesis in R6/1 mice, but no changes in microglial CD200R1 (Comella-Bolla et al., 2019). This study suggests that neuron-microglia communication through CD200-CD200R1 interaction is not compromised, and CD200 up-regulation could represent a neurotrophic signal to sustain neuronal function in the latest stages of HD (Comella-Bolla et al., 2019). Conversely, the altered FKN-CX3CR1 axis emerges as a specific pathological mechanism in neuron-microglia communication in HD, leading to the impairment of microglial homeostatic activity.
Taken together, our results reveal a key role for FKN in the pathophysiology of HD. FKN-CX3CR1 signaling deficits in HD lead to abnormal neuron-microglia interactions, which may contribute to the early striatal synaptic plasticity dysfunction characteristic of this neurological disease. However, further functional analysis might elucidate the critical contribution of microglial phagocytic activity to the pathological synaptic loss in the striatum. Similarly, many key aspects about the role of the FKN-CX3CR1 axis in microglia-mediated synaptic pruning and plasticity during neurodegeneration remain to be clarified. Learning more about the intricate roles that microglia play outside of their classic inflammatory response to damage could give us more insight into HD pathophysiology, allowing for the exploration of new therapeutic approaches for this neurological disorder.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.
Ethics Statement
The studies involving human participants were reviewed and approved by the Comissió de Bioètica (CBUB) Unversitat de Barcelona, Barcelona, Spain. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the CEEA-UB (Comitè Ètic d’Experimentació Animal de la Universitat de Barcelona) University of Barcelona, Barcelona, Spain.
Author Contributions
AK, MS, MM, and MR contributed to the conception and design of the study. AK, MS, JA, and MR designed the experiments. AK, EG-G, MS, AC-B, and AM performed all the experiments. MS, MM, and MR performed the statistical analysis. JA, JC, and MR got financial support. AK, EG-G, and MR wrote the manuscript. All authors contributed to the manuscript revision, and read and approved the submitted version.
Funding
This study was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (Spain), under projects no. SAF2017-88076-R (JA and MR) and RTI2018-099001-B-I00 (JC); Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (ERDF) [CIBERNED, to JA and RETICS (Red de Terapia Celular; RD16/0011/0012 to JC)], Spain; and CHDI Foundation (A-14079 to JC), United States.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The handling editor declared a shared affiliation, though no other collaboration, with the authors.
Acknowledgments
We are very grateful to Mireia Galofré and Georgina Bombau for their technical support on hiPSC culture and differentiation, and Ana Maria Lopez (María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017-0729, Ministry of Science, Innovation and Universities) for excellent mouse colony management. We thank Dr. Carme Solà (Institute of Biomedical Research of Barcelona, IibB-CSIC) for the critical scientific advisory. We are also grateful to the staff of the Confocal Microscopy Service of the Scientific and Technological Centers of the University of Barcelona (CCiTUB) and especially to Dr. Maria Calvo for technical support and advice on confocal microscopy and image analysis.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2020.00163/full#supplementary-material
Footnotes
References
Acharjee, S., Verbeek, M., Gomez, C. D., Bisht, K., Lee, B., Benoit, L., et al. (2018). Reduced microglial activity and enhanced glutamate transmission in the basolateral amygdala in early CNS autoimmunity. J. Neurosci. 38, 9019–9033. doi: 10.1523/JNEUROSCI.0398-18.2018
Arli, B., Irkec, C., Menevse, S., Yilmaz, A., and Alp, E. (2013). Fractalkine gene receptor polymorphism in patients with multiple sclerosis. Int. J. Neurosci. 123, 31–37. doi: 10.3109/00207454.2012.723079
Bachstetter, A. D., Morganti, J. M., Jernberg, J., Schlunk, A., Mitchell, S. H., Brewster, K. W., et al. (2011). Fractalkine and CX3CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol. Aging 32, 2030–2044. doi: 10.1016/j.neurobiolaging.2009.11.022
Battaglia, G., Cannella, M., Riozzi, B., Orobello, S., Maat-Schieman, M. L., Aronica, E., et al. (2011). Early defect of transforming growth factor β1 formation in Huntington’s disease. J. Cell. Mol. Med. 15, 555–571. doi: 10.1111/j.1582-4934.2010.01011.x
Bertollini, C., Ragozzino, D., Gross, C., Limatola, C., and Eusebi, F. (2006). Fractalkine/CX3CL1 depresses central synaptic transmission in mouse hippocampal slices. Neuropharmacology 51, 816–821. doi: 10.1016/j.neuropharm.2006.05.027
Burgold, J., Schulz-Trieglaff, E. K., Voelkl, K., Gutiérrez-Ángel, S., Bader, J. M., Hosp, F., et al. (2019). Cortical circuit alterations precede motor impairments in Huntington’s disease mice. Sci. Rep. 9:6634. doi: 10.1038/s41598-019-43024-w
Calvo, A., Moglia, C., Canosa, A., Cammarosano, S., Ilardi, A., Bertuzzo, D., et al. (2018). Common polymorphisms of chemokine (C-X3-C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: a population-based study. Muscle Nerve 57, 212–216. doi: 10.1002/mus.25653
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., et al. (2006). Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9, 917–924. doi: 10.1038/nn1715
Cardona, S. M., Kim, S. V., Church, K. A., Torres, V. O., Cleary, I. A., Mendiola, A. S., et al. (2018). Role of the fractalkine receptor in CNS autoimmune inflammation: new approach utilizing a mouse model expressing the human CX3CR1I249/M280 variant. Front. Cell. Neurosci. 12:365. doi: 10.3389/fncel.2018.00365
Carvalho, T. G., Alves-Silva, J., de Souza, J. M., Real, A. L. C. V., Doria, J. G., Vieira, E. L. M., et al. (2019). Metabotropic glutamate receptor 5 ablation accelerates age-related neurodegeneration and neuroinflammation. Neurochem. Int. 126, 218–228. doi: 10.1016/j.neuint.2019.03.020
Cepeda, C., Hurst, R. S., Calvert, C. R., Hernández-Echeagaray, E., Nguyen, O. K., Jocoy, E., et al. (2003). Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J. Neurosci. 23, 961–969. doi: 10.1523/jneurosci.23-03-00961.2003
Cepeda, C., Oikonomou, K. D., Cummings, D., Barry, J., Yazon, V. W., Chen, D. T., et al. (2019). Developmental origins of cortical hyperexcitability in Huntington’s disease: Review and new observations. J. Neurosci. Res. 97, 1624–1635. doi: 10.1002/jnr.24503
Chamera, K., Trojan, E., Szuster-Głuszczak, M., and Basta-Kaim, A. (2019). The potential role of dysfunctions in neuron - microglia communication in the pathogenesis of brain disorders. Curr. Neuropharmacol. doi: 10.2174/1570159X17666191113101629 [Epub ahead of print].
Chandrasekaran, S., and Bonchev, D. (2016). Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington’s disease. Comput. Struct. Biotechnol. J. 14, 117–130. doi: 10.1016/j.csbj.2016.02.001
Chang, K.-H., Wu, Y.-R., Chen, Y.-C., and Chen, C.-M. (2015). Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain. Behav. Immun. 44, 121–127. doi: 10.1016/j.bbi.2014.09.011
Chiu, I., Morimoto, E., Goodarzi, H., Liao, J., O’Keeffe, S., Phatnani, H., et al. (2013). A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385–401. doi: 10.1016/j.celrep.2013.06.018
Choi, K., Holly, E. N., Davatolhagh, M. F., Beier, K. T., and Fuccillo, M. V. (2019). Integrated anatomical and physiological mapping of striatal afferent projections. Eur. J. Neurosci. 49, 623–636. doi: 10.1111/ejn.13829
Comella-Bolla, A., Orlandi, J. G., Miguez, A., Straccia, M., García-Bravo, M., Bombau, G., et al. (2020). Human pluripotent stem cell-derived neurons are functionally mature in vitro and integrate into the mouse striatum following transplantation. Mol. Neurobiol. doi: 10.1007/s12035-020-01907-4 [Epub ahead of print].
Comella-Bolla, A., Valente, T., Miguez, A., Brito, V., Gines, S., Solà, C., et al. (2019). CD200 is up-regulated in R6/1 transgenic mouse model of Huntington’s disease. PLoS One 14:e0224901. doi: 10.1371/journal.pone.0224901
Creus-Muncunill, J., Badillos-Rodríguez, R., Garcia-Forn, M., Masana, M., Garcia-Díaz Barriga, G., Guisado-Corcoll, A., et al. (2019). Increased translation as a novel pathogenic mechanism in Huntington’s disease. Brain 142, 3158–3175. doi: 10.1093/brain/awz230
Creus-Muncunill, J., and Ehrlich, M. E. (2019). Cell-autonomous and non-cell-autonomous pathogenic mechanisms in Huntington’s Disease: insights from in vitro and in vivo models. Neurotherapeutics 16, 957–978. doi: 10.1007/s13311-019-00782-9
Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., et al. (2014). Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 17, 513–521. doi: 10.1038/nn.3668
Cummings, D. M., Milnerwood, A. J., Dallérac, G. M., Vatsavayai, S. C., Hirst, M. C., and Murphy, K. P. S. J. (2007). Abnormal cortical synaptic plasticity in a mouse model of Huntington’s disease. Brain Res. Bull. 72, 103–107. doi: 10.1016/j.brainresbull.2006.10.016
Deiva, K., Geeraerts, T., Salim, H., Leclerc, P., Héry, C., Hugel, B., et al. (2004). Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. Eur. J. Neurosci. 20, 3222–3232. doi: 10.1111/j.1460-9568.2004.03800.x
Deng, Y. P., Wong, T., Bricker-Anthony, C., Deng, B., and Reiner, A. (2013). Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington’s disease mice. Neurobiol. Dis. 60, 89–107. doi: 10.1016/j.nbd.2013.08.009
Derecki, N. C., Cronk, J. C., Lu, Z., Xu, E., Abbott, S. B. G., Guyenet, P. G., et al. (2012). Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105–109. doi: 10.1038/nature10907
Di Pardo, A., Alberti, S., Maglione, V., Amico, E., Cortes, E. P., Elifani, F., et al. (2013). Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease. Mol. Brain 6:55. doi: 10.1186/1756-6606-6-55
Espinosa-Parrilla, J. F., Martínez-Moreno, M., Gasull, X., Mahy, N., and Rodríguez, M. J. (2015). The L-type voltage-gated calcium channel modulates microglial pro-inflammatory activity. Mol. Cell. Neurosci. 64, 104–115. doi: 10.1016/j.mcn.2014.12.004
Ferrante, R. J., Gutekunst, C. A., Persichetti, F., McNeil, S. M., Kowall, N. W., Gusella, J. F., et al. (1997). Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17, 3052–3063. doi: 10.1523/JNEUROSCI.17-09-03052.1997
Finneran, D. J., and Nash, K. R. (2019). Neuroinflammation and fractalkine signaling in Alzheimer’s disease. J. Neuroinflammation 16:30. doi: 10.1186/s12974-019-1412-9
Ghiglieri, V., Campanelli, F., Marino, G., Natale, G., Picconi, B., and Calabresi, P. (2019). Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington’s disease. J. Neurosci. Res. 97, 1655–1664. doi: 10.1002/jnr.24521
Gunner, G., Cheadle, L., Johnson, K. M., Ayata, P., Badimon, A., Mondo, E., et al. (2019). Sensory lesioning induces microglial synapse elimination via ADAM10 and fractalkine signaling. Nat. Neurosci. 22, 1075–1088. doi: 10.1038/s41593-019-0419-y
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., et al. (1998). Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U.S.A. 95, 10896–10901. doi: 10.1073/pnas.95.18.10896
Hawes, S. L., Gillani, F., Evans, R. C., Benkert, E. A., and Blackwell, K. T. (2013). Sensitivity to theta-burst timing permits LTP in dorsal striatal adult brain slice. J. Neurophysiol. 110, 2027–2036. doi: 10.1152/jn.00115.2013
Hd iPSC Consortium. (2017). Developmental alterations in Huntington’s disease neural cells and pharmacological rescue in cells and mice. Nat. Neurosci. 20, 648–660. doi: 10.1038/nn.4532
Hickman, S. E., Allison, E. K., Coleman, U., Kingery-Gallagher, N. D., and El Khoury, J. (2019). Heterozygous CX3CR1 deficiency in microglia restores neuronal β-amyloid clearance pathways and slows progression of Alzheimer’s like-disease in PS1-APP mice. Front. Immunol. 10:2780. doi: 10.3389/fimmu.2019.02780
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712–716. doi: 10.1126/science.aad8373
Hong, S. L., Cossyleon, D., Hussain, W. A., Walker, L. J., Barton, S. J., and Rebec, G. V. (2012). Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington’s disease. PLoS One 7:e47026. doi: 10.1371/journal.pone.0047026
Hoshiko, M., Arnoux, I., Avignone, E., Yamamoto, N., and Audinat, E. (2012). Deficiency of the microglial receptor CX3CR1 impairs postnatal functional development of thalamocortical synapses in the barrel cortex. J. Neurosci. 32, 15106–15111. doi: 10.1523/JNEUROSCI.1167-12.2012
Hoshino, K., Hayakawa, M., and Morimoto, Y. (2017). Minocycline prevents the impairment of hippocampal long-term potentiation in the septic mouse. Shock 48, 209–214. doi: 10.1097/SHK.0000000000000847
Kwan, W., Träger, U., Davalos, D., Chou, A., Bouchard, J., Andre, R., et al. (2012). Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 122, 4737–4747. doi: 10.1172/JCI64484
Lauro, C., Catalano, M., Trettel, F., and Limatola, C. (2015). Fractalkine in the nervous system: neuroprotective or neurotoxic molecule? Ann. N. Y. Acad. Sci. 1351, 141–148. doi: 10.1111/nyas.12805
Lauro, C., Cipriani, R., Catalano, M., Trettel, F., Chece, G., Brusadin, V., et al. (2010). Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death. Neuropsychopharmacology 35, 1550–1559. doi: 10.1038/npp.2010.26
Lee, J.-M., Ivanova, E. V., Seong, I. S., Cashorali, T., Kohane, I., Gusella, J. F., et al. (2007). Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 3:e135. doi: 10.1371/journal.pgen.0030135
Liu, J., Copland, D. A., Horie, S., Wu, W.-K., Chen, M., Xu, Y., et al. (2013). Myeloid cells expressing VEGF and arginase-1 following uptake of damaged retinal pigment epithelium suggests potential mechanism that drives the onset of choroidal angiogenesis in mice. PLoS One 8:e72935. doi: 10.1371/journal.pone.0072935
Liu, Y., Wu, X.-M., Luo, Q.-Q., Huang, S., Yang, Q.-W. Q., Wang, F.-X., et al. (2015). CX3CL1/CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK/PKC pathway. J. Cereb. Blood Flow Metab. 35, 1623–1631. doi: 10.1038/jcbfm.2015.97
Liu, Z., Condello, C., Schain, A., Harb, R., and Grutzendler, J. (2010). CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis. J. Neurosci. 30, 17091–17101. doi: 10.1523/JNEUROSCI.4403-10.2010
Lopez-Lopez, A., Gamez, J., Syriani, E., Morales, M., Salvado, M., Rodríguez, M. J., et al. (2014). CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS One 9:e96528. doi: 10.1371/journal.pone.0096528
Luo, P., Chu, S.-F., Zhang, Z., Xia, C.-Y., and Chen, N.-H. (2019). Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases. Brain Res. Bull. 146, 12–21. doi: 10.1016/j.brainresbull.2018.11.017
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506. doi: 10.1016/s0092-8674(00)81369-0
Marco, S., Giralt, A., Petrovic, M. M., Pouladi, M. A., Martínez-Turrillas, R., Martínez-Hernández, J., et al. (2013). Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington’s disease models. Nat. Med. 19, 1030–1038. doi: 10.1038/nm.3246
Mattison, H. A., Nie, H., Gao, H., Zhou, H., Hong, J.-S., and Zhang, J. (2013). Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. J. Neuroimmunol. 257, 110–115. doi: 10.1016/j.jneuroim.2013.02.008
Miguez, A., Barriga, G. G. D., Brito, V., Straccia, M., Giralt, A., Ginés, S., et al. (2015). Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington’s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum. Mol. Genet. 24, 4958–4970. doi: 10.1093/hmg/ddv218
Miller, B. R., Walker, A. G., Barton, S. J., and Rebec, G. V. (2011). Dysregulated neuronal activity patterns implicate corticostriatal circuit dysfunction in multiple rodent models of Huntington’s disease. Front. Syst. Neurosci. 5:26. doi: 10.3389/fnsys.2011.00026
Miyamoto, A., Wake, H., Ishikawa, A. W., Eto, K., Shibata, K., Murakoshi, H., et al. (2016). Microglia contact induces synapse formation in developing somatosensory cortex. Nat. Commun. 7:12540. doi: 10.1038/ncomms12540
Molero, A. E., Arteaga-Bracho, E. E., Chen, C. H., Gulinello, M., Winchester, M. L., Pichamoorthy, N., et al. (2016). Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington’s disease. Proc. Natl. Acad. Sci. U.S.A. 113, 5736–5741. doi: 10.1073/pnas.1603871113
Morigaki, R., and Goto, S. (2017). Striatal vulnerability in Huntington’s disease: neuroprotection versus neurotoxicity. Brain Sci. 7:63. doi: 10.3390/brainsci7060063
Nishiyori, A., Minami, M., Ohtani, Y., Takami, S., Yamamoto, J., Kawaguchi, N., et al. (1998). Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett. 429, 167–172. doi: 10.1016/s0014-5793(98)00583-3
Nithianantharajah, J., Barkus, C., Murphy, M., and Hannan, A. J. (2008). Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington’s disease transgenic mice. Neurobiol. Dis. 29, 490–504. doi: 10.1016/j.nbd.2007.11.006
Pagani, F., Paolicelli, R. C., Murana, E., Cortese, B., Di Angelantonio, S., Zurolo, E., et al. (2015). Defective microglial development in the hippocampus of Cx3cr1 deficient mice. Front. Cell. Neurosci. 9:111. doi: 10.3389/fncel.2015.00111
Pandur, E., Tamási, K., Pap, R., Varga, E., Miseta, A., and Sipos, K. (2019). Fractalkine iinduces hepcidin expression of BV-2 microglia and causes iron accumulation in SH-SY5Y cells. Cell. Mol. Neurobiol. 39, 985–1001. doi: 10.1007/s10571-019-00694-4
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., et al. (2011). Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458. doi: 10.1126/science.1202529
Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R., Lafaille, J. J., et al. (2013). Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596–1609. doi: 10.1016/j.cell.2013.11.030
Paxinos, G., and Franklin, K. B. J. (2012). Paxinos and Franklin’s the Mouse Brain in Stereotaxic Coordinates. Cambridge, MA: Academic Press.
Pérez-Severiano, F., Escalante, B., Vergara, P., Ríos, C., and Segovia, J. (2002). Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation. Brain Res. 951, 36–42. doi: 10.1016/s0006-8993(02)03102-5
Puigdellívol, M., Cherubini, M., Brito, V., Giralt, A., Suelves, N., Ballesteros, J., et al. (2015). A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington’s disease. Hum. Mol. Genet. 24, 7265–7285. doi: 10.1093/hmg/ddv426
Ragozzino, D., Di Angelantonio, S., Trettel, F., Bertollini, C., Maggi, L., Gross, C., et al. (2006). Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons. J. Neurosci. 26, 10488–10498. doi: 10.1523/JNEUROSCI.3192-06.2006
Ransohoff, R. M., and Perry, V. H. (2009). Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119–145. doi: 10.1146/annurev.immunol.021908.132528
Renoir, T., Pang, T. Y., Shikano, Y., Li, S., and Hannan, A. J. (2015). Loss of the sexually dimorphic neuro-inflammatory response in a transgenic mouse model of Huntington’s disease. J. Huntingtons. Dis. 4, 297–303. doi: 10.3233/JHD-150153
Rogers, J. T., Morganti, J. M., Bachstetter, A. D., Hudson, C. E., Peters, M. M., Grimmig, B. A., et al. (2011). CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J. Neurosci. 31, 16241–16250. doi: 10.1523/JNEUROSCI.3667-11.2011
Saavedra, A., Giralt, A., Rué, L., Xifró, X., Xu, J., Ortega, Z., et al. (2011). Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington’s disease: a STEP in the resistance to excitotoxicity. J. Neurosci. 31, 8150–8162. doi: 10.1523/JNEUROSCI.3446-10.2011
Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., et al. (2001). Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161–172. doi: 10.1093/jnen/60.2.161
Schafer, D. P., Lehrman, E. K., Heller, C. T., and Stevens, B. (2014). An engulfment assay: a protocol to assess interactions between CNS phagocytes and neurons. J. Vis. Exp. 88:51482. doi: 10.3791/51482
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., et al. (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691–705. doi: 10.1016/j.neuron.2012.03.026
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., et al. (2016). Schizophrenia risk from complex variation of complement component 4. Nature 530, 177–183. doi: 10.1038/nature16549
Shrivastava, K., Gonzalez, P., and Acarin, L. (2012). The immune inhibitory complex CD200/CD200R is developmentally regulated in the mouse brain. J. Comp. Neurol. 520, 2657–2675. doi: 10.1002/cne.23062
Siew, J. J., Chen, H. M., Chen, H. Y., Chen, H. L., Chen, C. M., Soong, B. W., et al. (2019). Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat. Commun. 10:3473. doi: 10.1038/s41467-019-11441-0
Song, Q., Liu, M.-G., and Zhuo, M. (2015). Minocycline does not affect long-term potentiation in the anterior cingulate cortex of normal adult mice. Mol. Pain 11:25. doi: 10.1186/s12990-015-0025-2
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., et al. (2007). Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain 130, 1759–1766. doi: 10.1093/brain/awm044
Tang, Z., Gan, Y., Liu, Q., Yin, J.-X., Liu, Q., Shi, J., et al. (2014). CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J. Neuroinflammation 11:26. doi: 10.1186/1742-2094-11-26
Telezhkin, V., Straccia, M., Yarova, P., Pardo, M., Yung, S., Vinh, N.-N., et al. (2018). Kv7 channels are upregulated during striatal neuron development and promote maturation of human iPSC-derived neurons. Pflugers. Arch. 470, 1359–1376. doi: 10.1007/s00424-018-2155-7
Tremblay, M.-È., Lowery, R. L., and Majewska, A. K. (2010). Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 8:e1000527. doi: 10.1371/journal.pbio.1000527
Unschuld, P. G., Joel, S. E., Liu, X., Shanahan, M., Margolis, R. L., Biglan, K. M., et al. (2012). Impaired cortico-striatal functional connectivity in prodromal Huntington’s Disease. Neurosci. Lett. 514, 204–209. doi: 10.1016/j.neulet.2012.02.095
Van der Plas, E., Langbehn, D. R., Conrad, A. L., Koscik, T. R., Tereshchenko, A., Epping, E. A., et al. (2019). Abnormal brain development in child and adolescent carriers of mutant huntingtin. Neurology 93, e1021–e1030. doi: 10.1212/WNL.0000000000008066
Vashishtha, M., Ng, C. W., Yildirim, F., Gipson, T. A., Kratter, I. H., Bodai, L., et al. (2013). Targeting H3K4 trimethylation in Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 110, E3027–E3036. doi: 10.1073/pnas.1311323110
Veldman, M. B., and Yang, X. W. (2018). Molecular insights into cortico-striatal miscommunications in Huntington’s disease. Curr. Opin. Neurobiol. 48, 79–89. doi: 10.1016/j.conb.2017.10.019
Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S., and Nabekura, J. (2009). Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci. 29, 3974–3980. doi: 10.1523/JNEUROSCI.4363-08.2009
Wake, H., Moorhouse, A. J., Miyamoto, A., and Nabekura, J. (2013). Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci. 36, 209–217. doi: 10.1016/j.tins.2012.11.007
Wang, Q., Rowan, M. J., and Anwyl, R. (2004). β-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24, 6049–6056. doi: 10.1523/JNEUROSCI.0233-04.2004
Wilkes, F. A., Abaryan, Z., Ching, C. R. K., Gutman, B. A., Madsen, S. K., Walterfang, M., et al. (2019). Striatal morphology and neurocognitive dysfunction in Huntington disease: the IMAGE-HD study. Psychiatry Res. Neuroimaging 291, 1–8. doi: 10.1016/j.pscychresns.2019.07.003
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., and Guo, J.-F. (2017). Microglial activation in the pathogenesis of Huntington’s disease. Front. Aging Neurosci. 9:193. doi: 10.3389/fnagi.2017.00193
York, E. M., Ledue, J. M., Bernier, L. P., and Macvicar, B. A. (2018). 3DMorph automatic analysis of microglial morphology in three dimensions from ex vivo and in vivo imaging. eNeuro 5:ENEURO.0266-18.2018. doi: 10.1523/ENEURO.0266-18.2018
Keywords: huntingtin, CX3CL1, microglia, corticostriatal pathway, synaptic pruning, human iPSC
Citation: Kim A, García-García E, Straccia M, Comella-Bolla A, Miguez A, Masana M, Alberch J, Canals JM and Rodríguez MJ (2020) Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington’s Disease. Front. Cell. Neurosci. 14:163. doi: 10.3389/fncel.2020.00163
Received: 29 March 2020; Accepted: 15 May 2020;
Published: 18 June 2020.
Edited by:
Albert Giralt, University of Barcelona, SpainReviewed by:
Anthony Hannan, The University of Melbourne, AustraliaRosa Chiara Paolicelli, Université de Lausanne, Switzerland
Copyright © 2020 Kim, García-García, Straccia, Comella-Bolla, Miguez, Masana, Alberch, Canals and Rodríguez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jordi Alberch, alberch@ub.edu; Josep M. Canals, jmcanals@ub.edu; Manuel J. Rodríguez, marodriguez@ub.edu
†These authors have contributed equally to this work